Granulomatous Inflammation

Granulomatous inflammation is a distinctive pattern of chronic inflammation characterized by the formation of granulomas, compact, organized aggregates of epithelioid histiocytes, often surrounded by a rim of lymphocytes and containing multinucleated giant cells. This tissue response is a hallmark of numerous infectious and non-infectious diseases, including tuberculosis , sarcoidosis , Crohn's disease , and the ANCA-associated vasculitides ^[2]A1a[8]D5. It is also a central feature of drug-induced reactions, foreign body responses, and certain autoimmune conditions ^[5]D5[6]D5.

Synonyms and Related Terms

• Granulomatous disease (imprecise umbrella term)
• Epithelioid granuloma (histologic description)
• Granulomatous reaction (clinical context)

Key Definitions

• Granuloma: A compact, organized collection of epithelioid histiocytes, with or without multinucleated giant cells, lymphocytes, and variable necrosis.
• Epithelioid histiocyte: An activated macrophage with abundant eosinophilic cytoplasm, indistinct cell borders, and an elongated, pale nucleus resembling epithelial cells.
• Multinucleated giant cell: A fused aggregate of epithelioid histiocytes, often with a peripheral ring of nuclei (Langhans type) or scattered nuclei (foreign-body type).
• Caseous necrosis: Acellular, eosinophilic, granular necrosis with loss of tissue architecture, most commonly associated with Mycobacterium tuberculosis infection.
• Non-caseating granuloma: A granuloma lacking central necrosis, typical of sarcoidosis and Crohn's disease .
• Suppurative granuloma: A granuloma with a central neutrophilic abscess, seen in cat-scratch disease, fungal infections , and lymphogranuloma venereum.
• Foreign body granuloma: A granuloma formed around non-digestible material (e.g., suture, talc, silicone), often with numerous foreign-body giant cells.
• Necrotizing granuloma: A granuloma with non-caseous, often fibrinoid necrosis, characteristic of granulomatosis with polyangiitis (GPA) and other vasculitides ^[8]D5.

Morphological Classification of Granulomas

Clinical Significance

Granulomatous inflammation is not a diagnosis but a histologic pattern that demands a systematic search for its root cause. The underlying etiology ranges from infectious agents (e.g., Mycobacterium tuberculosis , Mycobacterium leprae , fungi ) to immune-mediated processes (e.g., sarcoidosis , Crohn's disease , ANCA-associated vasculitis ), toxins, and neoplasms. The wrong diagnosis can delay treatment for a curable infection or expose a patient to unnecessary immunosuppression. Recognition of the granuloma subtype, caseating versus non-caseating, suppurative versus necrotizing, narrows the differential and guides further testing.

The diverse etiologies that trigger this stereotypic tissue reaction are examined in the next section.

Pearl: The type of granuloma (caseating vs. non-caseating, suppurative vs. necrotizing) narrows the differential diagnosis but is never pathognomonic; correlation with clinical presentation, microbiologic cultures, and serologic markers (e.g., ACE, ANCA, QuantiFERON) is essential before committing to therapy.

Granulomatous inflammation arises from a diverse array of triggers, and identifying the specific cause is the cornerstone of management . The etiologies span infectious agents, foreign materials, autoimmune processes, and systemic inflammatory disorders. Below are the major categories, each with representative causes supported by the current evidence.

Infectious Causes

Mycobacterium tuberculosis remains the most common infectious cause worldwide, with granuloma formation being the hallmark of tuberculosis pathology ^[15]D5[16]D5. Other mycobacterial species can also induce granulomas. In the larynx, non-tuberculous infectious causes include leishmaniasis , histoplasmosis , laryngoscleroma , cryptococcosis , sporotrichosis , and botryomycosis ^[10]C4. Fungal infections, particularly in immunocompromised hosts, are well-recognized triggers. Parasitic infections such as leishmaniasis produce granulomatous responses in affected tissues.

Foreign Body Reactions

Foreign body granulomas (FBGs) result from implanted materials that provoke a persistent inflammatory response. The most extensively documented iatrogenic cause is collagen-stimulating cosmetic fillers. A systematic review of 117 patients (mean age 52.63 years, range 29-78) found that polymethylmethacrylate (PMMA) accounted for 35.04% of FBGs, followed by poly-L-lactic acid (PLLA) at 30.77%, calcium hydroxylapatite (CaHA) at 27.35%, polycaprolactone (PCL) at 4.27%, and dextran-based fillers at 2.56% ^[9]C4. Nodules were the most common presentation (82.91%), and the perioral region was the highest-risk site. Latency ranged from 1 week to 15 years (mean 20.18 months), with nondegradable fillers having a longer latency ^[9]C4.

Another important foreign body trigger is inflammatory pseudotumor (IP) after total hip arthroplasty . While initially associated with metal-on-metal bearings, IP can occur with other bearing types. Recognized risk factors include female sex, genetic predispositions, large femoral head size, modular femoral stem designs, elevated metal ion levels, and polyethylene wear debris ^[13]D5. IP contributes to prosthesis failure through both mechanical and inflammatory mechanisms.

Autoimmune and Systemic Causes

Sarcoidosis is the prototypical systemic granulomatous disease of unknown cause, though it is believed to be triggered by an unidentified antigen in genetically susceptible individuals ^[14]D5[18]D5. It is a polygenic, multifactorial disorder with environmental and lifestyle influences ^[18]D5. Cutaneous sarcoidosis can provide clues to systemic involvement and prognosis ^[17]D5.

Type I interferonopathies, specifically systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren disease (SjD), and dermatomyositis (DM), are associated with an increased risk of developing cutaneous sarcoidosis, granuloma annulare , lichen planus , and morphea ^[11]B3b. These findings support a role for type I interferon pathway dysregulation in granulomatous dermatoses.

Crohn disease is another granulomatous disorder, though it is not directly covered in the provided references; the association is well-established in the literature. Vasculitides such as granulomatosis with polyangiitis can also present with granulomatous inflammation, but these are not detailed in the current evidence.

Drug-Induced and Other Causes

Drug-induced granulomatous inflammation is not specifically addressed in the provided abstracts, but certain medications (e.g., immune checkpoint inhibitors, tumor necrosis factor inhibitors) are known to trigger granulomatous reactions. The absence of a drug-induced category in the available evidence does not preclude its clinical relevance; clinicians should consider drug history when evaluating unexplained granulomas.

Summary of Etiologies

Pearl: In patients with laryngeal granulomas of unknown cause, repeat biopsy and consideration of infectious etiologies like leishmaniasis or histoplasmosis is essential, especially when autoimmune workup is negative ^[10]C4.

From the diverse etiologies described above, a common pathogenic cascade emerges: persistent antigen drives a chronic inflammatory response that organizes into a structured granuloma. The process unfolds through distinct but overlapping phases of macrophage recruitment, activation, epithelioid transformation, and spatial immune regulation, with the ultimate outcome, containment or progression, determined by the balance of protective and suppressive mechanisms.

The Core Cascade: Antigen Persistence to Granuloma Formation

Granuloma formation begins when the host fails to eliminate a persistent stimulus, triggering the recruitment of monocytes and macrophages to the site of inflammation ^[22]D5. Macrophages differentiate into epithelioid cells under the influence of IFN-γ and TNF-α , which are produced by activated Th1 and Th17.1 cells ^[14]D5. Fusion of epithelioid macrophages forms Langhans giant cells, a hallmark of many granulomas. In sarcoidosis , this process is driven by an unidentified antigen that sustains Th1, Th17, and Th17.1 responses, with an exaggerated IFN-γ signature ^[14]D5. In tuberculosis , Mycobacterium tuberculosis actively manipulates macrophage activation states through bacterial effector proteins, shaping granuloma architecture to favor its survival ^[22]D5.

Cytokine and Cellular Orchestration

Granuloma stability depends on a precise cytokine gradient. Tumor necrosis factor (TNF) is essential for maintaining granuloma integrity; excessive or insufficient TNF can skew toward a less protective phenotype ^[24]D5. Interleukin-12 (IL-12) drives Th1 differentiation, while IL-17 recruits neutrophils and promotes matrix metalloproteinase (MMP) activity, contributing to tissue remodeling ^[24]D5. In eosinophilic granulomatosis with polyangiitis (EGPA), IL-5 drives eosinophil differentiation, activation, and survival, creating a distinct eosinophil-rich granulomatous inflammation ^[21]C4[23]D5. Regulatory T cells (Treg) expressing Foxp3+ accumulate in early granulomas, where they exert an anti-inflammatory effect to limit immunopathology; in bovine paratuberculosis, Foxp3+ T cells are highest in focal (latency) lesions and decline in diffuse forms ^[19]C4.

Metabolic Reprogramming in Granuloma Macrophages

Hypoxia within the granuloma core drives a metabolic shift toward aerobic glycolysis, with increased activity of the pentose phosphate pathway (PPP) ^[25]D5. The PPP provides NADPH, which protects macrophages against oxidative stress, and ribose-5-phosphate for biosynthesis. mTOR signaling is a key regulator of macrophage differentiation; its activation promotes the epithelioid phenotype ^[25]D5. L-arginine metabolism is also reprogrammed: inducible nitric oxide synthase (iNOS) generates nitric oxide for antimicrobial activity, while arginase activity diverts arginine toward polyamine and collagen synthesis, promoting fibrosis ^[25]D5.

Spatial Immune Regulation and Suppressive Niches

Advanced imaging of human TB granulomas reveals a spatially organized immunosuppressive microenvironment. The core contains iNOS+ macrophages, surrounded by a cuff of fibroblasts and macrophages, with a neutrophil rim at the periphery ^[22]D5. Critically, the granuloma is an IFN-γ-depleted zone enriched for TGF-β , Foxp3+ Tregs, and IDO1+ PD-L1+ myeloid cells that suppress effector T cell function ^[20]C4. PD-L1 expression on myeloid cells is associated with progression to active TB and treatment response, indicating that these suppressive niches are clinically relevant ^[20]C4. In noninfectious granulomatous diseases like sarcoidosis, deficient regulatory pathways fail to counterbalance the hyperactive T cell response, creating a self-perpetuating inflammatory loop that drives fibrotic progression ^[14]D5.

Microbial Effectors and Host Circuits

In mycobacterial and other infections, bacterial effector proteins actively remodel host cytokine responses and macrophage activation states to shape granuloma fate ^[22]D5. For example, Mycobacterium tuberculosis can induce a regulatory niche that favors bacterial persistence. Conversely, host-driven programs involving type I interferon (IFN-I) signaling are increasingly implicated in granulomatous dermatoses such as cutaneous sarcoidosis and granuloma annulare, likely through amplification of inflammatory circuits ^[11]B3b. The balance between protective type 1/17 responses and suppressive mechanisms determines whether the granuloma contains infection or becomes a site of pathogen persistence and host tissue damage ^[24]D5.

Pearl: The granuloma is a double-edged sword, its protective function depends on precise, coordinated immune responses; tipping the balance too far toward suppression (Treg, PD-L1, TGF-β) or excessive inflammation (IFN-γ, TNF-α, MMPs) leads to either pathogen persistence or progressive fibrosis.

From the pathogenetic pathways described above, granulomas can be classified by their inciting agent and histologic appearance, a framework that directly guides the differential diagnosis. Two broad etiologic categories, foreign body and immune-mediated, encompass most granulomas, and within each, the presence or absence of necrosis further refines the differential.

Classification by Etiology

Foreign body granulomas arise from inert, non-degradable material that the host cannot eliminate. The inciting agent is visible under polarized light or special stains in many cases. Common culprits include silicone (from breast implants or facial fillers), cyanoacrylate glue (used in venous closure), muslin (aneurysm wrapping), and various dermal fillers . In a systematic review of 303 patients with adverse reactions to facial fillers, 87.1% showed foreign body granuloma on histopathology ^[27]C4. Silicone is particularly notorious for distant migration: cases of eyelid granulomas have been documented years after breast augmentation or facial filler injection, even when the patient reported only hyaluronic acid use ^[30]C4[31]C4. Cyanoacrylate glue reactions manifest as phlebitis, hypersensitivity, or foreign body granuloma, with proposed mechanisms involving polymer degradation products ^[26]C4. Muslin-induced granulomas after aneurysm wrapping produce characteristic MRI findings (elevated T2 signal, increased diffusion-weighted signal, thin rim enhancement) that can mimic abscess or tumor ^[32]C4.

Immune granulomas result from a cell-mediated immune response to persistent antigen, typically microbial or self-antigen. The classic example is the caseating granuloma of tuberculosis , composed of epithelioid histiocytes, Langhans giant cells, and central caseous necrosis ^[33]C4. Non-caseating immune granulomas characterize sarcoidosis , Crohn's disease , and granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). GLILD, occurring in 10-20% of CVID patients, shows non-necrotizing granulomas with lymphocytic interstitial pneumonitis and follicular bronchiolitis, often misdiagnosed as sarcoidosis ^[29]D5.

Morphological Subtypes

The distinction between caseating and non-caseating necrosis is critical: caseous necrosis is highly specific for mycobacterial or fungal infection ^[33]C4, whereas non-caseating granulomas prompt a broader workup including sarcoidosis, autoimmune disease, and foreign body reaction. Suppurative granulomas, with their neutrophilic core, point toward bacterial pathogens like Bartonella or Chlamydia. Necrotizing granulomas with vasculitis should raise suspicion for GPA.

These morphological patterns are not absolute, overlap exists. For example, tuberculosis can occasionally show non-caseating granulomas in immunocompromised hosts, and sarcoidosis may rarely exhibit fibrinoid necrosis. The histologic classification therefore serves as a starting point, to be integrated with clinical, serologic, and microbiologic data. The next section details the full histopathologic spectrum, including special stains and immunohistochemistry that further characterize each subtype.

Pearl: The presence of caseous necrosis is highly specific for mycobacterial or fungal infection; its absence does not exclude tuberculosis, but should prompt consideration of sarcoidosis, fungal infection, or foreign body reaction, especially when polarized light reveals birefringent material.

Building on the morphological classification, the microscopic features of granuloma s provide the definitive tissue diagnosis. The core histologic elements are consistent across etiologies, epithelioid histiocytes, multinucleated giant cells, a surrounding lymphocytic cuff, and variable necrosis, but the pattern and distribution of these components guide the differential diagnosis ^[40]D5.

Epithelioid Histiocytes

The hallmark of a granuloma is the epithelioid histiocyte, a transformed macrophage with abundant eosinophilic cytoplasm, indistinct cell borders, and an elongated, often curved nucleus with fine chromatin. These cells are CD68+/CD163+ by immunohistochemistry and are tightly apposed, forming cohesive clusters. In sarcoidosis, the granuloma density, measured as granulomas per cytoblock, can be significantly higher using a crown-cut needle (mean 8.3 vs. 3.8, p<0.05) compared with a conventional needle, underscoring the importance of sampling technique for histologic yield ^[34]A1b. Epithelioid histiocytes may also be found scattered in the stroma of central giant cell granulomas, where they are admixed with plump mononuclear cells ^[40]D5.

Multinucleated Giant Cells

Fusion of epithelioid histiocytes produces multinucleated giant cells. Two classic morphologies are recognized:

• Langhans giant cells: nuclei arranged peripherally in a horseshoe or ring pattern. They are typical of tuberculosis and sarcoidosis, though not specific.
• Foreign body giant cells: nuclei haphazardly distributed throughout the cytoplasm. They are seen in foreign body reactions and some fungal infections.

In sarcoidosis, the numerical yield of histiocytes is also improved with crown-cut sampling (mean 502 vs. 186 per cytoblock, p<0.05) ^[34]A1b. Giant cells may contain inclusions such as Schaumann bodies (lamellated basophilic concretions) or asteroid bodies (stellate eosinophilic structures), which are more common in sarcoidosis but not pathognomonic.

Lymphocytic Rim and Stromal Changes

Mature granulomas are surrounded by a cuff of lymphocytes, predominantly CD4+ T cells, and occasional plasma cells. The stroma may show fibrosis, especially in chronic or healing granulomas. In oral cavity giant cell granulomas, the mononuclear cells and giant cells are embedded in a mesenchymal stromal background that can be myxoid or collagenized ^[40]D5.

Necrosis Patterns

Necrosis within granulomas is a critical discriminator:

• Caseous necrosis: eosinophilic, acellular, granular debris with loss of architecture. It is characteristic of tuberculosis and some fungal infections.
• Non-caseous necrosis: less common, seen in sarcoidosis (fibrinoid necrosis or none) and in granulomatosis with polyangiitis (geographic necrosis with neutrophils).
• Suppurative necrosis: neutrophil-rich, seen in cat scratch disease (Bartonella) and lymphogranuloma venereum.

The absence of necrosis is typical of sarcoidosis, foreign body reactions, and leprosy (tuberculoid type).

Associated Histologic Features

Additional features help narrow the etiology:

• Vasculitis: granulomatous vasculitis is a hallmark of granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA) ^[39]D5.
• Eosinophils: prominent in EGPA, drug reactions, and parasitic infections.
• Neutrophils and microabscesses: suggest infectious causes (e.g., actinomycosis , nocardiosis ) or inflammatory bowel disease.
• Fibrosis and hyalinization: seen in long-standing sarcoidosis and in the fibroinflammatory lesions of the sinonasal tract, such as eosinophilic angiocentric fibrosis (now considered part of IgG4-related disease ) ^[39]D5.

The table below summarizes the key histologic distinctions among common granulomatous entities.

Diagnostic Utility of Histology

Histologic evaluation remains the gold standard for diagnosing granulomatous inflammation. The combination of granuloma architecture, necrosis pattern, giant cell type, and associated inflammation often points to a specific etiology, guiding targeted microbiologic, serologic, and molecular testing. For example, in sarcoidosis, the diagnostic yield of EBUS-TBNA approaches 80% with either conventional or crown-cut needles, though the latter provides superior tissue quality for histologic quantification ^[34]A1b. In oral cavity giant cell granulomas, the distinction from brown tumor of hyperparathyroidism or giant cell tumor requires correlation with serum calcium and PTH levels ^[40]D5.

Pearl: The single most actionable histologic feature is the presence of caseous necrosis, when seen, the clinician should pursue an infectious workup (AFB/GMS stains, culture, PCR) before considering non-infectious causes.

The histologic patterns described above translate into a wide spectrum of clinical presentations that vary by organ system and underlying etiology. Recognition of these patterns is essential for prompt diagnosis and targeted workup.

Presenting Symptoms

Onset is typically insidious, with symptoms progressing over weeks to months. The timeline varies by cause: infectious granulomas (e.g., tuberculosis) may present with subacute systemic symptoms, while drug-induced reactions can develop after a prolonged latency period averaging months to years ^[42]C4.

Pulmonary involvement is the most common presentation across granulomatous diseases. Patients report cough, sputum production, chest pain, and dyspnea. A chest radiograph may reveal a mass, as in the case of a 52-year-old smoker with a 50 pack-year history who presented with cough and a right upper lobe mass ^[50]C4. Mediastinal lymph node tuberculosis can cause chest pain and dyspnea from compression ^[45]C4.

Cutaneous manifestations include papules, plaques, nodules, and erythroderma. Palisaded neutrophilic and granulomatous dermatitis (PNGD) presents with symmetrical, skin-colored to red papules, often on the elbows and extremities, and may coalesce into erythroderma with high fever ^[47]C4. Interstitial granulomatous drug reactions and granuloma annulare are typically localized to the skin ^[42]C4. Lupus pernio and violaceous plaques are characteristic of cutaneous sarcoidosis ^[17]D5.

Hepatic involvement presents as right upper quadrant pain, weight loss, and a mass on imaging. IgG4-related hepatic inflammatory pseudotumor (IgG4-HIPT) can mimic malignancy, with arterial phase enhancement and increased metabolic activity on ¹⁸F-FDG PET/CT ^[46]C4. Immune checkpoint inhibitor-induced hepatic pseudotumors are asymptomatic in most cases ^[48]C4. Isolated tuberculous granuloma of the falciform ligament causes persistent right upper abdominal pain ^[49]C4.

Gastrointestinal and esophageal involvement is rare but can cause severe dysphagia and weight loss, as seen in a 24-year-old woman with a circumferential esophageal stricture from an IgG4-related inflammatory pseudotumor ^[43]C4.

Otologic granulomas present with acute profound hearing loss and vertigo. Post-stapedotomy reparative granuloma, for example, requires urgent surgical exploration to salvage hearing ^[44]C4.

Lymph node enlargement, especially mediastinal, is a hallmark of sarcoidosis and tuberculosis.

Neurological Examination Findings

Neurosarcoidosis may present with cranial nerve palsies (most commonly facial nerve), peripheral neuropathy , and autonomic dysfunction. Examination should include assessment of cranial nerves, motor strength, sensation, reflexes, and orthostatic vital signs. The presence of neurological symptoms in a patient with known sarcoidosis should prompt consideration of CNS involvement, though the reviewed cases do not provide specific neurological data ^[17]D5.

Phenotypic Variants

Red Flags

Symptoms requiring urgent action include:

• Respiratory compromise from mediastinal mass or pulmonary parenchymal involvement (pneumothorax, restriction).
• Autonomic instability or acute cranial nerve deficits suggesting neurosarcoidosis.
• Acute hearing loss with vertigo after stapes surgery, surgical exploration is indicated ^[44]C4.
• Severe dysphagia with weight loss from esophageal pseudotumor ^[43]C4.
• High fever with erythroderma in PNGD, which may mimic toxic shock syndrome ^[47]C4.

Atypical Presentations

Several presentations are easily missed:

• Serum IgG4-negative IgG4-RD: Normal circulating IgG4 does not exclude the diagnosis; tissue biopsy is essential ^[46]C4.
• PNGD without underlying disease: Typically associated with SLE or other autoimmune conditions, but can occur in isolation ^[47]C4.
• Hepatic pseudotumor from ICI: Asymptomatic lesion on imaging, easily mistaken for metastasis; biopsy prevents unnecessary interventions ^[48]C4.
• Tuberculous granuloma of the falciform ligament: Mimics malignancy on PET/CT; requires histologic confirmation ^[49]C4.
• Granulomatous neoplasm at EBUS-TBNA site: Can occur after diagnostic aspiration of tuberculous abscess; treatable with cryotherapy ^[45]C4.
• Post-stapedotomy granuloma from acellular graft: A novel foreign-body reaction to a bioprosthetic material ^[44]C4.

These varied presentations underscore the need for systematic diagnostic workup, which is covered in the next section.

Pearl: Always consider iatrogenic causes (drug-induced, post-procedural) in patients with granulomatous inflammation and no clear infectious or systemic disease, drug withdrawal or surgical excision can be curative.

The clinical presentation of granulomatous inflammation, as detailed in the preceding section, is highly variable and organ-dependent. Establishing a definitive diagnosis therefore hinges on a systematic workup that begins with tissue biopsy and proceeds through a tailored combination of microbiologic, serologic, and imaging studies. The goal is to identify the underlying cause, infectious, autoimmune, neoplastic, or foreign body, while avoiding unnecessary delays in treatment.

Gold-Standard Test: Tissue Biopsy with Histologic Examination

Tissue biopsy with histologic examination is the gold standard for diagnosing granulomatous inflammation. The biopsy must be adequate in size and representative of the lesion. For laryngeal granulomas, repeat biopsies are often necessary; in one series, four of 30 patients required open biopsy after non-diagnostic microlaryngoscopy ^[10]C4. For hepatic granulomas , a liver biopsy is required, with prevalence on biopsy ranging from 1% to 15% ^[53]D5. Bone marrow granulomas are typically an incidental finding on trephine biopsy ^[54]D5. In all cases, the histologic pattern, non-caseating, caseating, suppurative, fibrin-ring, or foreign-body type, guides the differential (see Section 4).

Laboratory Studies

Serologic testing is adjunctive and context-dependent. For suspected sarcoidosis, serum angiotensin-converting enzyme (ACE) and soluble interleukin-2 receptor (sIL-2R) levels may be elevated but are neither sensitive nor specific. For suspected vasculitis, ANCA testing is critical: MPO-ANCA positivity supports eosinophilic granulomatosis with polyangiitis (EGPA), as illustrated by a case where ANCA testing (>134 U/mL) was the diagnostic turning point in a patient with Guillain-Barré-like neuropathy ^[58]C4. For suspected infection, serologies for Brucella, Coxiella burnetii (Q fever), Histoplasma, and Toxoplasma should be considered based on exposure history. Eosinophilia (>30%) raises suspicion for EGPA or parasitic infection ^[58]C4.

Imaging

Imaging serves two roles: identifying disease extent and guiding biopsy. High-resolution CT of the chest is essential for suspected sarcoidosis (bilateral hilar lymphadenopathy, perilymphatic nodules). 18F-FDG PET/CT can reveal metabolically active granulomas and guide biopsy to the most accessible site. For filler-induced granulomas, high-frequency ultrasound (12-18 MHz) accurately identifies lesion type with an ultrasound-pathology concordance rate of 85.7% ^[51]C4. For neurosarcoidosis , MRI with gadolinium may show leptomeningeal enhancement, but biopsy remains the key differentiator from mimics ^[55]D5.

Special Stains and Molecular Studies

Every granuloma biopsy should undergo a panel of special stains to exclude infection, even when clinical suspicion is low. The table below summarizes the standard stains and their targets.

Polymerase chain reaction (PCR) on fresh or paraffin-embedded tissue is increasingly used for rapid identification of M. tuberculosis, Bartonella, Coxiella, and fungi. In bone marrow biopsies with granulomas of unknown cause, untargeted metagenomics may become a standard diagnostic tool ^[54]D5.

Diagnostic Algorithm

A stepwise approach minimizes missed diagnoses:

1. Obtain adequate tissue biopsy from the most accessible involved site (e.g., liver, lymph node, skin, lung, bone marrow). For deep-seated lesions, image-guided or open biopsy may be required.
2. Perform histologic examination to classify granuloma type (non-caseating, caseating, suppurative, fibrin-ring, foreign-body).
3. Apply special stains (AFB, GMS, PAS, Gram, Warthin-Starry) on all granuloma biopsies.
4. Send tissue for culture (mycobacterial, fungal, bacterial) and PCR for M. tuberculosis complex, Bartonella, and Coxiella as indicated.
5. Conduct serologic testing based on clinical context: ANCA (EGPA, GPA), ACE/sIL-2R (sarcoidosis), Brucella agglutinins, Coxiella phase I/II antibodies, HIV, syphilis serology.
6. Perform imaging (CT chest, PET/CT, or high-frequency ultrasound) to assess extent and guide further biopsy if initial sample is non-diagnostic.
7. Consider repeat biopsy if initial results are non-diagnostic and clinical suspicion remains high ^[10]C4.

Pearl: In any granuloma biopsy, always order AFB and GMS stains upfront, even when infection seems unlikely, because a positive result changes management from immunosuppression to antimicrobial therapy, and a false-negative can lead to catastrophic dissemination.

Once the diagnostic workup confirms granulomatous inflammation, the histologic pattern, caseating versus non-caseating, necrotizing versus non-necrotizing, combined with clinical context and microbiologic/molecular results, narrows the differential. A structured approach reduces diagnostic delay, especially in atypical presentations ^[59]D5, ^[64]C4.

Histologic Pattern as the First Branch Point

Organ System Clues

Each organ system narrows the differential. In the lung, isolated non-caseating granulomas suggest sarcoidosis, hypersensitivity pneumonitis, or berylliosis; cavitary lesions raise concern for TB or fungal infection. CNS granulomas require exclusion of tuberculosis, especially if necrotizing ^[62]C4; NICE lesions occur after endovascular therapy with foreign body emboli ^[63]C4. In the skin, foreign body granulomas from fillers or threads are common ^[9]C4, ^[60]D5; lupus pernio is specific to sarcoidosis. Bone lesions: xanthogranulomatous osteomyelitis mimics malignancy ^[61]C4. Pediatric patients with refractory granulomatous disease should prompt immunogenetic evaluation for inborn errors of immunity such as STAT1 deficiency ^[64]C4.

Overlap Syndromes and Diagnostic Pitfalls

Sarcoidosis can present with necrotizing granulomas mimicking tuberculosis, especially in the CNS ^[62]C4. Conversely, tuberculosis can produce non-caseating granulomas in immunocompromised hosts. Overlap syndromes occur when sarcoidosis coexists with other granulomatous diseases ^[59]D5. Negative microbiologic tests do not rule out infection, metagenomic next-generation sequencing (mNGS) and PCR on biopsy material increase yield, particularly for Aspergillus or Mycobacterium tuberculosis ^[65]C4. ANCA testing distinguishes vasculitic causes; negative ANCA with necrotizing granulomas and vasculitis should raise suspicion for NSG ^[62]C4.

Pearl: The single most common misdiagnosis is calling non-caseating granulomas “sarcoidosis” without excluding infection, always send tissue for AFB and fungal culture, even if AFB smear is negative, and use molecular methods when clinical suspicion persists ^[64]C4.

Having excluded infection and other causes through the diagnostic workup, management pivots to treating the underlying etiology and, for non-infectious granulomatous disorders, suppressing the aberrant immune response. The approach must be tailored to the specific disease, disease severity, and organ involvement, with a growing emphasis on glucocorticoid-sparing strategies and targeted biologic therapies.

Step 1: Treat the Underlying Cause

For infectious granulomatous diseases, antimicrobial therapy is the cornerstone. In tuberculosis, standard multidrug regimens remain first-line; emerging nanocarrier systems (biodegradable polymeric, lipid-based, and extracellular vesicles) aim to enhance drug delivery directly to granulomas, though these remain preclinical ^[15]D5 (5). For fungal or parasitic causes, appropriate antifungals or antiparasitics are indicated. When a drug-induced granulomatous reaction is identified, the offending agent should be discontinued.

Step 2: Immunosuppression for Non-Infectious Granulomatous Disorders

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Systemic glucocorticoids ( GCs ) remain the mainstay of induction and maintenance therapy, but long-term toxicity is a pervasive challenge ^[23]D5 (5). The goal is to achieve remission while minimizing GC exposure. Recent pivotal trials have incorporated stringent GC dose thresholds (e.g., prednisone ≤4 mg/day) into primary endpoints ^[73]D5 (5).

Biologic therapies targeting the IL-5/IL-5R axis have transformed EGPA management. In the MANDARA trial and its open-label extension, benralizumab (anti-IL-5Rα) and mepolizumab (anti-IL-5) administered every 4 weeks produced durable remission rates: at week 104, 62.1% of benralizumab/benralizumab patients and 67.7% of mepolizumab/benralizumab patients were in remission (BVAS = 0 and OGC ≤4 mg/day) ^[66]A1b (1b). By weeks 101-104, 43.9% and 43.5% had withdrawn from OGCs, respectively. A meta-analysis of eight studies (396 patients) confirmed a significant OCS dose reduction of -8.25 mg/day (95% CI -9.39 to -7.10) and a complete remission rate of 56.8% ^[67]A1a (1a). Adverse events occurred in 21.9% of patients, with only one discontinuation due to an AE.

Conventional immunosuppressants ( cyclophosphamide , azathioprine, methotrexate ) and rituximab remain options, especially for severe vasculitic manifestations, though robust RCT evidence in EGPA is limited ^[23]D5 (5). Expert recommendations advocate a phenotype-driven strategy distinguishing eosinophilic from vasculitic features ^[72]D5 (5).

Table 1: Biologic Therapy for EGPA

Data from MANDARA OLE ^[66]A1b (1b). Switching from mepolizumab to benralizumab enhanced eosinophil depletion and OGC sparing.

Generalized Granuloma Annulare (GGA)

A 2025 systematic review of 689 patients proposes a stepwise algorithm ^[69]D5 (5):

• First-line: Hydroxychloroquine and phototherapy (PUVA > UVA1 > nb-UVB).
• Bridging therapy: Oral corticosteroids plus high-potency topical steroids or calcineurin inhibitors for extensive/rapidly progressive disease.
• Second-line: Sulfones (e.g., dapsone); oral retinoids (e.g., isotretinoin) as alternatives.
• Refractory: Off-label anti-TNF-α agents or JAK inhibitors; methotrexate or cyclosporine as alternatives.

Subcutaneous Granuloma Annulare (SGA)

SGA is predominantly pediatric (median age 6 years). Surgical excision is common and effective (68.1% of patients), but spontaneous improvement occurs in 87.0% of conservatively managed cases, with 60.0% completely self-resolving ^[68]D5 (5). Intralesional steroids may benefit non-resolving cases; topical steroids showed only 54.6% complete/partial resolution.

[[Kimura Disease]]

Management is multidisciplinary. In a retrospective series of 13 patients, treatments included surgical excision, glucocorticoids, methotrexate, low-dose radiotherapy, and observation, with remission achieved in 76.9% ^[71]C4 (4). Pre-treatment eosinophilia (absolute eosinophil count ≥1.77 × 10⁹/L) was associated with poorer outcomes.

Step 3: Refractory Disease and Escalation

For EGPA patients who fail or cannot taper GCs despite anti-IL-5/R therapy, consider adding conventional immunosuppressants (methotrexate, azathioprine) or rituximab, guided by ANCA status and vasculitic activity ^[23]D5 (5). In GGA, failure of first- and second-line therapies warrants a trial of anti-TNF or JAK inhibitors ^[69]D5 (5). For SGA, persistent or recurrent nodules may be re-excised or treated with intralesional steroids ^[68]D5 (5).

Controversies and Guideline Disagreement

Pearl: In EGPA, initiate anti-IL-5/R therapy (benralizumab or mepolizumab) early to achieve GC-free remission; the MANDARA trial demonstrates that 2-year remission rates exceed 60% with substantial OGC withdrawal, and switching from mepolizumab to benralizumab further depletes eosinophils ^[66]A1b (1b).

Five-year recurrence-free survival after surgical drainage of petrous apex cholesterol granuloma ranges from 46.0% with simple drainage to 97.1% when a nasoseptal mucosal flap is used ^[74]D5. This stark gradient illustrates the principle that prognosis in granulomatous inflammation is tightly linked to both the underlying etiology and the adequacy of treatment.

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Real-world outcomes with anti-IL-5/IL-5 receptor biologics show substantial improvement over 24 months. Remission (BVASv3 = 0 with prednisone ≤5 mg/day) at 24 months is achieved in 73.7% of patients on benralizumab 30 mg every 4-8 weeks, 81.0% on mepolizumab 300 mg every 4 weeks, and 50.0% on mepolizumab 100 mg every 4 weeks ^[75]B2b. Glucocorticoid-free status at 24 months reaches 63.2%, 85.7%, and 58.3%, respectively ^[75]B2b. A systematic review of 306 patients reported remission rates of 46-69% at 12 months and 66-71% at 24 months, with complete oral corticosteroid discontinuation in 32-68% of patients ^[3]B2a. Prior mepolizumab use may lower remission likelihood (37% vs 60%) ^[3]B2a. Eosinophil suppression is near-complete with benralizumab and correlates with pulmonary function improvement ^[75]B2b. Treatment persistence at 24 months is high, with discontinuations driven mainly by inadequate control of ENT or respiratory manifestations ^[75]B2b.

Kimura Disease

In a retrospective series of 13 patients, remission was achieved in 76.9% after treatments including surgical excision, glucocorticoids, methotrexate , or low-dose radiotherapy ^[71]C4. Patients with poor outcomes had significantly higher absolute eosinophil counts (median 1.77 vs 0.90 × 10⁹/L, P = 0.04) and eosinophil percentages (median 21.4% vs 12.2%, P = 0.03) ^[71]C4. Imaging misdiagnosis occurred in 38.5% of cases, underscoring the need for histopathologic confirmation ^[71]C4. Long-term sequelae include urine abnormalities and mild renal dysfunction ^[71]C4.

Cholesterol Granuloma of the Petrous Apex

Endoscopic endonasal marsupialization with a nasoseptal mucosal flap (NSMF) dramatically reduces recurrence. The 5-year estimated recurrence-free survival is 46.0% with simple drainage, 80.7% with drainage plus stenting, and 97.1% with NSMF ^[74]D5. In two cases with cranial nerve palsies, complete symptom recovery and maintained patency were observed over 5 years ^[74]D5.

Filler-Induced Granulomas

High-frequency ultrasound accurately classifies filler complications (concordance rate 85.7%) and guides treatment ^[51]C4. Non-HA filler granulomas respond better to noninvasive therapy, whereas granulomas without residual filler and HA-associated granulomas favor invasive treatment ^[51]C4. Invasive treatment yields greater improvement in indurations ^[51]C4.

ANCA-Associated Vasculitis (AAV) Overall

In a Lithuanian cohort (2012-2021), the standardized mortality ratio (SMR) for AAV decreased from 1.79 in 2013-2015 to 1.67 in 2019-2021, indicating improving but still elevated mortality ^[70]B2b. Mean age at death was 65.2 years, and life expectancy is reduced, especially when diagnosed at a young age ^[70]B2b.

Pearl: In EGPA, achieving GC-free remission by 24 months is a realistic goal in over 60% of patients with anti-IL-5/IL-5R therapy, but prior mepolizumab exposure may reduce the likelihood of remission ^[75]B2b.

Building on the prognostic data, several landmark studies have shaped the diagnostic and therapeutic approach to granulomatous inflammation. These investigations span the spectrum from molecular pathogenesis to clinical trials, providing the evidence base for current practice.

Endoscopic Ultrasound-Guided Fine-Needle Aspiration for Mediastinal Adenopathy

The prospective study by Fritscher-Ravens et al. (2011) established EUS-FNA as a pivotal diagnostic tool for differentiating tuberculosis from sarcoidosis in patients with mediastinal lymphadenopathy and negative bronchoscopic workup ^[79]B2b. In 72 consecutive patients, EUS-FNA achieved a sensitivity of 86% and specificity of 100% for tuberculosis, and 100% sensitivity and 93% specificity for sarcoidosis. The procedure provided a definitive diagnosis in 89% of cases that had eluded conventional methods, directly altering management by guiding anti-tuberculous therapy versus corticosteroid initiation. This study changed practice by making EUS-FNA the preferred next step after nondiagnostic bronchoscopy.

Bayesian Model for Differentiating Intestinal Tuberculosis from Crohn's Disease

Limsrivilai et al. (2017) conducted a meta-analysis of 38 studies (2,117 CD, 1,589 ITB patients) and constructed a Bayesian prediction model that integrates clinical, endoscopic, pathological, and imaging findings ^[83]A1a. The model, validated in 49 patients, showed 90.9% sensitivity and 92.6% specificity for diagnosing intestinal tuberculosis. Key discriminators favoring ITB included transverse ulcers, patulous ileocecal valve, confluent or submucosal granulomas, and positive interferon-γ release assay; features favoring CD included longitudinal ulcers, cobblestone appearance, perianal disease, and focally enhanced colitis. This model, available as a web application, provides a quantitative framework for a historically difficult differential diagnosis.

Granulomas as a Prognostic Marker in Crohn's Disease

Hong et al. (2019) performed a systematic review and meta-analysis of 19 studies examining the clinical significance of epithelioid granulomas in CD ^[84]B2a. Granuloma presence was associated with a more aggressive phenotype: higher odds of ileocolonic disease (OR 1.49, 95%), penetrating behavior (OR 1.48, 95%), perianal disease (OR 2.15, 95%), and increased biologic use (OR 1.66, 95%). Granulomas also predicted CD-associated hospitalization (OR 3.88, 95%). These findings support granuloma detection as a marker of disease severity that may guide earlier escalation to biologic therapy.

Immunoregulatory Landscape of Tuberculosis Granulomas

McCaffrey et al. (2022) used multiplexed ion beam imaging (MIBI-TOF) to map 37 proteins across 19 cell subsets in human TB granulomas ^[20]C4. They identified an IFN-γ-depleted microenvironment enriched for TGF-β, regulatory T cells, and IDO1+ PD-L1+ myeloid cells. Notably, PD-L1 expression in peripheral blood correlated with progression to active TB and treatment response. This study provides the first comprehensive spatial atlas of human TB granulomas, revealing local immunosuppressive programs with systemic manifestations, and identifies PD-L1 as a potential biomarker and therapeutic target.

Mesenchymal Stem Cells for Perianal Fistulas

Wang et al. (2023) conducted a systematic review and meta-analysis of clinical trials evaluating mesenchymal stem cell (MSC) therapy for complex perianal fistulas, a condition characterized by granulomatous inflammation ^[76]A1a. MSC therapy was superior to conventional treatment in short-term, long-term, and over-long-term follow-up, though not in medium-term. Subgroup analyses showed efficacy regardless of cell type, source, or dosage, with particularly promising results for Crohn's disease-related fistulas. This meta-analysis supports MSC therapy as a novel, effective option for complex perianal fistulas, potentially reducing the need for surgery and its associated morbidity.

Landmark Studies Summary

Pearl: When differentiating intestinal tuberculosis from Crohn's disease, use the validated Bayesian model ^[83]A1a that integrates clinical, endoscopic, and pathological features, it outperforms clinical gestalt and provides a probability calibrated to local prevalence.

Building on the landmark trials that established treatment paradigms, several professional societies have issued clinical practice guidelines to standardize care for granulomatous diseases. These guidelines address diagnosis, treatment, and monitoring, with notable updates in tuberculosis (TB) and Crohn's disease (CD) management .

Tuberculosis Guidelines

The ATS/CDC/ERS/IDSA 2025 guideline ^[90]A1c recommends all-oral, shorter regimens for drug-susceptible and drug-resistant TB. For pulmonary TB, a novel 4-month regimen is now preferred over the traditional 6-month course. Children with nonsevere TB can receive a shortened 4-month regimen. For drug-resistant TB, regimens containing bedaquiline , pretomanid , and linezolid (with or without moxifloxacin ) are recommended. The Tuberculous Meningitis International Research Consortium 2025 guideline ^[88]A1c provides evidence-based recommendations for diagnosis, anti-TB chemotherapy, adjunctive anti-inflammatory therapy, and neurocritical care, highlighting substantial knowledge gaps.

Crohn's Disease Guidelines

Multiple guidelines address CD, a prototypical granulomatous disease. The AGA 2025 living guideline ^[86]A1c recommends using higher-efficacy medications ( infliximab , adalimumab , ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy options in biologic-naïve patients. In patients with prior advanced therapy exposure, the AGA suggests higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib, ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). The guideline recommends against thiopurine monotherapy for induction but suggests it for maintenance, and recommends subcutaneous methotrexate over oral. Combination therapy with infliximab and thiopurines is preferred over infliximab alone. The ACG 2025 guideline ^[89]A1c similarly emphasizes shared decision-making and treat-to-target strategies. The APAGE 2026 guideline ^[85]A1c provides region-specific recommendations for Asia-Pacific, endorsing IL-23 p19 inhibitors (guselkumab, mirikizumab, risankizumab) and JAK inhibitors (tofacitinib, filgotinib, upadacitinib) with careful monitoring for herpes zoster . The ESGAR 2025 practice recommendations ^[91]A1c outline imaging protocols for luminal CD, prioritizing MR enterography and intestinal ultrasound over CT.

Biologic Therapy and Latent TB Screening

A 2025 joint position statement from the National Psoriasis Foundation and International Psoriasis Council ^[87]A1c states that routine testing for latent TB infection is not required in psoriasis patients treated with IL-17 or IL-23 inhibitors. This represents a shift from prior practice, though exceptions include patients on concomitant immunosuppression or those living in TB-endemic areas. This position may conflict with other guidelines that still recommend screening, particularly for TNF inhibitors.

Hidradenitis Suppurativa in Special Populations

The 2024 North American guideline ^[92]A1c provides 118 consensus statements for managing hidradenitis suppurativa in seven special populations, including those with TB infection, hepatitis B/C, and HIV. It emphasizes individualized risk assessment and multidisciplinary care.

Controversies and Guideline Disagreement

Pearl: The most practice-changing update is the shift to all-oral, shorter TB regimens (4 months for pulmonary TB) and the evolving consensus that routine latent TB screening may be unnecessary for IL-17/IL-23 inhibitors, though exceptions apply.